Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

T Fathi

Showing results (151-160 of 168) with videos related to

Pageof 17
Sort By:
Journal of the National Comprehensive Cancer Network : JNCCN|January 2, 2017
Myelodysplastic Syndromes, Version 2.2017, NCCN Clinical Practice Guidelines in OncologyPeter L Greenberg, Richard M Stone, Aref Al-Kali, et al.
Blood|December 17, 2019
Ivosidenib induces deep durable remissions in patients with newly diagnosed IDH1-mutant acute myeloid leukemiaGail J Roboz, Courtney D DiNardo, Eytan M Stein, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|January 6, 2021
NCCN Guidelines Insights: Acute Myeloid Leukemia, Version 2.2021Daniel A Pollyea, Dale Bixby, Alexander Perl, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|June 15, 2019
Acute Myeloid Leukemia, Version 3.2019, NCCN Clinical Practice Guidelines in OncologyMartin S Tallman, Eunice S Wang, Jessica K Altman, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|May 8, 2023
Acute Myeloid Leukemia, Version 3.2023, NCCN Clinical Practice Guidelines in OncologyDaniel A Pollyea, Jessica K Altman, Rita Assi, et al.
Cancer|December 21, 2019
A phase 1 study of the antibody-drug conjugate brentuximab vedotin with re-induction chemotherapy in patients with CD30-expressing relapsed/refractory acute myeloid leukemiaRupa Narayan, Traci M Blonquist, Ashkan Emadi, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|July 9, 2017
Acute Myeloid Leukemia, Version 3.2017, NCCN Clinical Practice Guidelines in OncologyMargaret R O'Donnell, Martin S Tallman, Camille N Abboud, et al.
Genes & Development|March 5, 2014
D-2-hydroxyglutarate produced by mutant IDH2 causes cardiomyopathy and neurodegeneration in miceEsra A Akbay, Javid Moslehi, Camilla L Christensen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 25, 2025
Ziftomenib in Relapsed or Refractory <i>NPM1</i>-Mutated AMLEunice S Wang, Pau Montesinos, James Foran, et al.
Blood|June 2, 2026
Ziftomenib with venetoclax and azacitidine in relapsed/refractory NPM1-mutated acute myeloid leukemiaEunice S Wang, Harry P Erba, Amer M Zeidan, et al.
Pageof 17

Showing results (151-160 of 168) with videos related to

Sort By:
Pageof 17
Journal of the National Comprehensive Cancer Network : JNCCN|January 2, 2017
Myelodysplastic Syndromes, Version 2.2017, NCCN Clinical Practice Guidelines in OncologyPeter L Greenberg, Richard M Stone, Aref Al-Kali, et al.
Blood|December 17, 2019
Ivosidenib induces deep durable remissions in patients with newly diagnosed IDH1-mutant acute myeloid leukemiaGail J Roboz, Courtney D DiNardo, Eytan M Stein, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|January 6, 2021
NCCN Guidelines Insights: Acute Myeloid Leukemia, Version 2.2021Daniel A Pollyea, Dale Bixby, Alexander Perl, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|June 15, 2019
Acute Myeloid Leukemia, Version 3.2019, NCCN Clinical Practice Guidelines in OncologyMartin S Tallman, Eunice S Wang, Jessica K Altman, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|May 8, 2023
Acute Myeloid Leukemia, Version 3.2023, NCCN Clinical Practice Guidelines in OncologyDaniel A Pollyea, Jessica K Altman, Rita Assi, et al.
Cancer|December 21, 2019
A phase 1 study of the antibody-drug conjugate brentuximab vedotin with re-induction chemotherapy in patients with CD30-expressing relapsed/refractory acute myeloid leukemiaRupa Narayan, Traci M Blonquist, Ashkan Emadi, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|July 9, 2017
Acute Myeloid Leukemia, Version 3.2017, NCCN Clinical Practice Guidelines in OncologyMargaret R O'Donnell, Martin S Tallman, Camille N Abboud, et al.
Genes & Development|March 5, 2014
D-2-hydroxyglutarate produced by mutant IDH2 causes cardiomyopathy and neurodegeneration in miceEsra A Akbay, Javid Moslehi, Camilla L Christensen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 25, 2025
Ziftomenib in Relapsed or Refractory <i>NPM1</i>-Mutated AMLEunice S Wang, Pau Montesinos, James Foran, et al.
Blood|June 2, 2026
Ziftomenib with venetoclax and azacitidine in relapsed/refractory NPM1-mutated acute myeloid leukemiaEunice S Wang, Harry P Erba, Amer M Zeidan, et al.
Pageof 17